Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.84
CDNA's Cash-to-Debt is ranked lower than
68% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. CDNA: 0.84 )
Ranked among companies with meaningful Cash-to-Debt only.
CDNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 2.25 Max: N/A
Current: 0.84
Equity-to-Asset 0.36
CDNA's Equity-to-Asset is ranked lower than
73% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. CDNA: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
CDNA' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.26  Med: 0.47 Max: 0.68
Current: 0.36
-15.26
0.68
Piotroski F-Score: 3
Altman Z-Score: -3.01
Beneish M-Score: -1.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -62.97
CDNA's Operating Margin % is ranked lower than
72% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. CDNA: -62.97 )
Ranked among companies with meaningful Operating Margin % only.
CDNA' s Operating Margin % Range Over the Past 10 Years
Min: -62.97  Med: -7.67 Max: 4.58
Current: -62.97
-62.97
4.58
Net Margin % -78.93
CDNA's Net Margin % is ranked lower than
74% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. CDNA: -78.93 )
Ranked among companies with meaningful Net Margin % only.
CDNA' s Net Margin % Range Over the Past 10 Years
Min: -78.93  Med: -20.39 Max: 2.86
Current: -78.93
-78.93
2.86
ROE % -94.59
CDNA's ROE % is ranked lower than
82% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. CDNA: -94.59 )
Ranked among companies with meaningful ROE % only.
CDNA' s ROE % Range Over the Past 10 Years
Min: -94.59  Med: -38.72 Max: -38.72
Current: -94.59
-94.59
-38.72
ROA % -39.23
CDNA's ROA % is ranked lower than
68% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. CDNA: -39.23 )
Ranked among companies with meaningful ROA % only.
CDNA' s ROA % Range Over the Past 10 Years
Min: -51.23  Med: -29.68 Max: 2.2
Current: -39.23
-51.23
2.2
ROC (Joel Greenblatt) % -991.96
CDNA's ROC (Joel Greenblatt) % is ranked lower than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. CDNA: -991.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CDNA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -991.96  Med: -78.64 Max: 71
Current: -991.96
-991.96
71
GuruFocus has detected 3 Warning Signs with CareDx Inc $CDNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CDNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CDNA Guru Trades in Q1 2016

Chuck Royce 85,917 sh (+15.46%)
» More
Q2 2016

CDNA Guru Trades in Q2 2016

Chuck Royce 134,745 sh (+56.83%)
» More
Q3 2016

CDNA Guru Trades in Q3 2016

Chuck Royce 247,618 sh (+83.77%)
» More
Q4 2016

CDNA Guru Trades in Q4 2016

Chuck Royce 426,361 sh (+72.18%)
» More
» Details

Insider Trades

Latest Guru Trades with CDNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 8071
Compare:NAS:CHEK, NAS:CAPN, NAS:DRIO, OTCBB:INIS, OTCPK:SYGWF, NAS:TROV, NAS:BIOC, OTCPK:PRFMF, OTCPK:TDSGF, OTCPK:GNWSF, OTCPK:ILIU, NAS:WGBS, NAS:OPGN, OTCPK:LXXGF, AMEX:PTN, OTCPK:CRRVF, OTCPK:MDIT, NAS:GENE, OTCPK:MHTX, NAS:ROKA » details
CareDx Inc is a commercial stage company. The Company develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime.

CareDx Inc was incorporated in the State of Delaware on December 21, 1998 as Hippocratic Engineering, Inc. In April 1999, the Company changed its name to BioCardia, Inc., in June 2002 to Expression Diagnostics, Inc., in July 2007 to XDx, Inc. and in March 2014 to CareDx, Inc. The Company completed its initial public offering on July 22, 2014. The Company is a commercial stage company. The Company is engaged in developing, marketing and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), an FDA-cleared test, is a blood-based test used to monitor for acute cellular rejection in heart transplant recipients. AlloMap uses gene expression technology to aid in the identification of heart transplant recipients at low risk of rejection. It provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. It can be used for heart transplant recipients 15 years of age or older 55 days post-transplant. The Company is also engaged in developing additional testing solutions in the heart transplant market and new testing solutions in other organ transplant markets. It is engaged in applying next generation sequencing platforms to detect and quantitate genetic differences between cell-free DNA (cfDNA) in the blood stream emanating from the donor heart and cfDNA emanating from the transplant recipient. The Company markets AlloMap to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators and nurse practitioners. The Company has 16 issued United States patents, one pending United States patent application, and three pending patent applications outside the United States related to transplant. Its solution for heart transplant recipients competes against existing diagnostic tests utilized by pathologists, which, in the case of heart transplant rejection, generally involve evaluating biopsy. It operations are subjects to a variety of federal, state and local environmental and safety laws and regulations.

Ratios

vs
industry
vs
history
PB Ratio 0.93
CDNA's PB Ratio is ranked higher than
96% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. CDNA: 0.93 )
Ranked among companies with meaningful PB Ratio only.
CDNA' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.06 Max: 3.16
Current: 0.93
0.84
3.16
PS Ratio 0.59
CDNA's PS Ratio is ranked higher than
93% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. CDNA: 0.59 )
Ranked among companies with meaningful PS Ratio only.
CDNA' s PS Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.06 Max: 3.9
Current: 0.59
0.53
3.9
Current Ratio 0.89
CDNA's Current Ratio is ranked lower than
90% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. CDNA: 0.89 )
Ranked among companies with meaningful Current Ratio only.
CDNA' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.66 Max: 6.74
Current: 0.89
0.64
6.74
Quick Ratio 0.70
CDNA's Quick Ratio is ranked lower than
90% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. CDNA: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
CDNA' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.61 Max: 6.62
Current: 0.7
0.61
6.62
Days Inventory 77.88
CDNA's Days Inventory is ranked lower than
51% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. CDNA: 77.88 )
Ranked among companies with meaningful Days Inventory only.
CDNA' s Days Inventory Range Over the Past 10 Years
Min: 21.99  Med: 25.76 Max: 77.88
Current: 77.88
21.99
77.88
Days Sales Outstanding 45.78
CDNA's Days Sales Outstanding is ranked higher than
71% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. CDNA: 45.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDNA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.99  Med: 33.31 Max: 45.78
Current: 45.78
16.99
45.78
Days Payable 73.83
CDNA's Days Payable is ranked higher than
61% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. CDNA: 73.83 )
Ranked among companies with meaningful Days Payable only.
CDNA' s Days Payable Range Over the Past 10 Years
Min: 24.85  Med: 38.77 Max: 73.83
Current: 73.83
24.85
73.83

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.30
CDNA's Price-to-Median-PS-Value is ranked higher than
90% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. CDNA: 0.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDNA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.04 Max: 1.32
Current: 0.3
0.27
1.32
Earnings Yield (Greenblatt) % -73.56
CDNA's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. CDNA: -73.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -80.39  Med: 2.5 Max: 3.9
Current: -73.56
-80.39
3.9

More Statistics

Revenue (TTM) (Mil) $36.42
EPS (TTM) $ -2.24
Short Percentage of Float1.69%
52-Week Range $1.38 - 6.08
Shares Outstanding (Mil)21.28
» More Articles for CDNA

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CAREDX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Mar 15 2017
CareDx Reports Preliminary Fourth Quarter and FY 2016 Financial Results Mar 15 2017
CareDx Closes New $25 Million Debt Facility Mar 15 2017
AlloSure Featured in Journal of Applied Laboratory Medicine Mar 14 2017
AlloSure Featured in Journal of the American Society of Nephrology Mar 09 2017
CareDx to acquire SBT Resolver™ HLA Typing Products from Illumina Jan 24 2017
CAREDX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Jan 23 2017
CAREDX, INC. Files SEC form 8-K, Regulation FD Disclosure Dec 23 2016
ETFs with exposure to CareDx, Inc. : December 8, 2016 Dec 08 2016
CAREDX, INC. Financials Nov 23 2016
ETFs with exposure to CareDx, Inc. : November 16, 2016 Nov 16 2016
CAREDX, INC. Files SEC form 10-Q, Quarterly Report Nov 15 2016
CareDx, Inc. :CDNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 Nov 11 2016
Edited Transcript of CDNA earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 10 2016
CAREDX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Heart Transplant Patients Warn That CMS Decision Could Deprive Them Of Needed Care Oct 26 2016
AlloSure® Validation Highlighted by Journal of Molecular Diagnostics Press Release Oct 11 2016
Loads of Insider Selling at Red Hat Inc. (RHT) and Argan Inc. (AGX), Plus 3 Other Notable Insider... Oct 05 2016
CMS Proposal Threatens Availability of Standard of Care Blood Test to Heart Transplant Patients Oct 03 2016
CMS Proposal Threatens Availability Of Standard Of Care Blood Test To Heart Transplant Patients Oct 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)